Category Archives: Financing

Like Warren Buffett, J&J Throws Down Incubator Gauntlet . . .Who’s Next?

When people talk about Johnson and Johnson’s new San Diego incubator, Janssen Labs, they can’t help but be a little bit skeptical about the fact that J&J isn’t taking any options or first-rights to compounds developed by its incubator tenants….

Share

Five New Trends in Biotech Venture

The cover story for BioWorld Insight this week is about the biotech venture capital world, and how despite its much-publicized contraction, there’s a lot of exciting stuff going on like established firms closing new funds, established players regrouping to form…

Share

He Said What?!?! Best Biotech Quotes of 2011

As BioWorld Insight readers know, our “Word on the Street” column provides a sample of the most entertaining and thought-provoking quotes our staff stumbles upon each week. Some are gathered during interviews, some gleaned from analyst reports, and some overheard…

Share

The Good, the Bad and . . . the Huh? A 2011 Biotech Recap

The past year brought the biotech sector a mixed bag of news. Some of it was positive – for instance, the FDA picked up its drug approval pace in 2011 and, in some cases, even surprised the most hardened biotech…

Share

Send Me an Angel: More VC Alternatives on the Rise

It seems to me that an increasing number of start-ups have been boot-strapping their way through preclinical without venture capital lately. I have no quantitative data to back this up. But it’s a feeling I had earlier this year, too,…

Share

The Small IPO: Not Dead Yet? Regulation A Debated

The biotech industry has long known it’s getting harder and harder for a small company to go public. As John Craighead, managing director of investor relations and business development for the Biotechnology Industry Organization, said during a recent conference, about…

Share

An Optimist’s Take on Funding Options for Small Biotechs

No, that’s not a typo. I’m feeling optimistic about fundraising opportunities for small biotechs. Yes, I know we’re seeing venture firms pull back on an almost weekly basis (Prospect Ventures, Scale Venture Partners, etc.). And yes, I know the NVCA…

Share

Biotech Fundraising Plummets in Q3, but Will it Turn on a Dime?

Biotech companies raised just $2.8 billion in the third quarter of 2011, according to an analysis published in Monday’s BioWorld Insight. That’s a 60 percent drop from the second quarter of this year, and – just in case you thought…

Share

What do Macroeconomics, Creativity and Upfront Payments Have in Common?

What do macroeconomics, creativity and upfront payments have in common? They’re all featured in this week’s issue of BioWorld Insight! I’m going to put on my long-discarded marketing hat for a minute and say I think we put together a…

Share

#BIO2011: Meeeeemories Light the Corners of My Mind

OK, I officially promise never to quote Barbra’s songs again . . .but, with the 2011 BIO International Convention just a mere three weeks ago – it seems like a distant memory for some of us and a blur for…

Share